Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Issue 5 (October 2012)

• Record Type: Journal Article
• Authors: Walker, Alison; Marcucci, Guido
• Is Part Of: Expert review of hematology. Volume 5:Issue 5(2012)
• Page Start: 547
• Page End: 558
• Publication Date: 2012-10
• Subjects: acute myeloid leukemia -- mutational analysis -- normal karyotype -- prognostic markers; Hematology -- Periodicals; 616.15005
• DOI: 10.1586/ehm.12.45
• Languages: English
• ISSNs: 1747-4086

Abstract

Chromosomal abnormalities are detected in 50–60% of patients with acute myeloid leukemia (AML) and are important predictors of prognosis and risk of relapse. The remaining patients, those with cytogenetically normal AML, are a seemingly homogeneous group that in fact consists of subsets of patients with distinct clinical outcomes. This heterogeneity is likely related to acquired gene mutations, as well as altered miRNA and gene-expression profiles, which occur within the group. The identification of recurrent molecular abnormalities has improved prognostication and provided insight into mechanisms of leukemogenesis for patients with cytogenetically normal AML, as well as led to the discovery of novel therapeutic targets. As the number of mutations continues to expand, bioinformatic algorithms that allow for integration of multiple markers will be necessary to provide optimal care for patients with this disease.